Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX) $2.92 +0.01 (+0.34%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$2.85▼$2.9250-Day Range$2.91▼$4.1352-Week Range$2.81▼$12.00Volume7,028 shsAverage Volume20,766 shsMarket Capitalization$16.50 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Akari Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside927.4% Upside$30.00 Price TargetShort InterestHealthy0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector440th out of 949 stocksPharmaceutical Preparations Industry199th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingAkari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Akari Therapeutics has a forecasted upside of 927.4% from its current price of $2.92.Amount of Analyst CoverageAkari Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.22% of the float of Akari Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently decreased by 36.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKTX. Previous Next 2.0 News and Social Media Coverage News SentimentAkari Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Akari Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioAkari Therapeutics has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akari Therapeutics Stock (NASDAQ:AKTX)Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Read More AKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKTX Stock News HeadlinesNovember 28, 2023 | sg.finance.yahoo.comAkari Therapeutics, Plc (CLA.F)November 24, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Climb Higher FridayNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 24, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.comNovember 24, 2023 | americanbankingnews.comAkari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 200 Day Moving Average of $3.64November 16, 2023 | finance.yahoo.comAkari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceNovember 14, 2023 | msn.comTravel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher TuesdayNovember 6, 2023 | finance.yahoo.comAkari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development ConferenceNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.October 3, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference 63 Day 1 on October 4 Register NowSeptember 29, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Reports First Half 2023 Financial Results and HighlightsSeptember 29, 2023 | finance.yahoo.comAkari Therapeutics Reports First Half 2023 Financial Results and HighlightsSeptember 27, 2023 | finance.yahoo.comAkari Therapeutics to Present at Emerging Growth ConferenceSeptember 21, 2023 | finance.yahoo.comAkari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax CreditSeptember 19, 2023 | finance.yahoo.comAkari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet NeedsSeptember 5, 2023 | finance.yahoo.comAkari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 31, 2023 | msn.comAkari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10August 21, 2023 | finance.yahoo.comBritish pharma opens U.S. headquarters in BostonAugust 18, 2023 | finance.yahoo.comAkari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical TrialsAugust 17, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces ADS Ratio ChangeAugust 15, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics, Plc Announces ADS Ratio ChangeAugust 15, 2023 | msn.comAkari Therapeutics announces ADS ratio changeAugust 15, 2023 | finance.yahoo.comAkari Therapeutics, Plc Announces ADS Ratio ChangeAugust 2, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory AffairsAugust 2, 2023 | finance.yahoo.comAkari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory AffairsJuly 27, 2023 | finance.yahoo.comAkari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell TransplantationJuly 19, 2023 | finanznachrichten.deAkari Therapeutics Plc: Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial OfficerSee More Headlines Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2020Today11/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKTX CUSIPN/A CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+934.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book6.04Miscellaneous Outstanding Shares5,650,000Free Float2,159,000Market Cap$16.39 million OptionableNot Optionable Beta1.22 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Rachelle Suzanne Jacques (Age 52)President, CEO & Director Comp: $1.38MMs. Wendy F. DiCicco CPA (Age 56)Interim Chief Financial Officer Ms. Melissa Bradford-Klug (Age 53)Chief Operating Officer Dr. Miles Nunn (Age 54)Chief Scientific Officer Dr. John F. Neylan III (Age 70)M.D., Executive VP & Chief Medical Officer Ms. Beth-Anne LangSenior Vice President of Regulatory AffairsAnnie MackFinancial ControllerMore ExecutivesKey CompetitorsUnicycive TherapeuticsNASDAQ:UNCYEquilliumNASDAQ:EQCalciMedicaNASDAQ:CALCQilian International Holding GroupNASDAQ:QLICocrystal PharmaNASDAQ:COCPView All CompetitorsInstitutional OwnershipSabby Management LLCSold 7,214,040 shares on 11/15/2023Ownership: 3.152%View All Institutional Transactions AKTX Stock Analysis - Frequently Asked Questions Should I buy or sell Akari Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKTX shares. View AKTX analyst ratings or view top-rated stocks. What is Akari Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 12 month price objectives for Akari Therapeutics' stock. Their AKTX share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 927.4% from the stock's current price. View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts. How have AKTX shares performed in 2023? Akari Therapeutics' stock was trading at $9.3980 on January 1st, 2023. Since then, AKTX stock has decreased by 68.9% and is now trading at $2.92. View the best growth stocks for 2023 here. Are investors shorting Akari Therapeutics? Akari Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 11,200 shares, a drop of 36.0% from the October 31st total of 17,500 shares. Based on an average trading volume of 15,200 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are short sold. View Akari Therapeutics' Short Interest. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics, Plc (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX). Who are Akari Therapeutics' major shareholders? Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%). View institutional ownership trends. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AKTX) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.